Tagrisso 40mg Tablets

About Tagrisso 40mg Tablets

Tagrisso 40mg Tablet contains Osimertinib, a targeted anticancer medication belonging to the protein kinase inhibitor class, used for the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) in adults. It works by blocking abnormal EGFR proteins that drive the growth and spread of cancer cells, helping to slow disease progression and improve treatment outcomes. Tagrisso 40mg Tablet may be prescribed as adjuvant therapy following complete surgical removal of lung cancer to reduce the risk of recurrence, as a first-line treatment for advanced or metastatic EGFR-positive NSCLC, or for patients whose cancer has progressed despite previous treatment options. Before starting therapy, patients should undergo EGFR mutation testing to determine whether their cancer is likely to respond to Osimertinib. This medication is not recommended for children and adolescents under 18 years of age. Patients should inform their healthcare provider about any history of kidney disease, heart conditions, eye disorders, or previous lung inflammation before beginning treatment. Immediate medical attention is necessary if symptoms such as difficulty breathing, persistent cough, fever, severe skin reactions, unusual bruising or bleeding, extreme tiredness, pale skin, or signs of infection occur during therapy. Regular medical monitoring helps ensure the safe and effective use of Tagrisso 40mg Tablet while supporting optimal outcomes in the treatment of EGFR-mutated lung cancer.